Dendritic Cell and CAR-T Therapies Market, 2014 - 2024
PR Newswire - Wed May 13, 1:01PM CDT
INTRODUCTIONCancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
After Failure Of Phase 3 Trial, Aerie Pharmaceuticals Struggles To Find Value
Edward Vranic, CFA - at Seeking Alpha - Tue Apr 28, 7:46AM CDT
EYES: 12.46 (-0.25), AERI: 11.26 (+0.01)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 102.30 (+0.47), INO: 7.97 (-0.02), NWBO: 8.12 (+0.07), MRK: 60.23 (+0.45), CLDX: 25.81 (+0.06), NLNK: 39.69 (+1.57), GALE: 1.35 (-0.01), IMUC: 0.48 (+0.01), NVS: 103.75 (-0.15)
Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 33.99 (+0.05), AMRN: 1.93 (+0.03)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 33.36 (+0.12), CASM: 1.26 (unch), AMRN: 1.93 (+0.03), XON: 40.08 (-0.90), OSIR: 17.29 (-0.18), CPIX: 6.69 (-0.01), AMED: 28.49 (-0.04), CTIC: 1.80 (+0.04), INSY: 59.00 (+0.17), ECYT: 6.02 (unch), CMRX: 40.15 (+0.31), KYTH: 46.55 (-0.10), TRIB: 16.37 (-0.27), GALE: 1.35 (-0.01), ARNA: 4.25 (unch), XLRN: 31.84 (-0.02), ACRX: 3.16 (-0.09), ENDP: 85.35 (+0.33), DPLO: 35.06 (+0.36), SLXP: 172.96 (+0.15), PPHM: 1.37 (+0.05), MYL: 70.67 (-0.86), CBPO: 101.56 (+0.67), RGEN: 41.63 (+0.26), HALO: 16.42 (+0.11), ALIM: 4.49 (-0.06), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02), DARA: 0.68 (-0.06), SCMP: 15.94 (-0.01), ICPT: 306.23 (-0.84), CDXS: 4.50 (-0.13), PCRX: 77.83 (+0.95), PBYI: 177.01 (+6.34), FOLD: 10.53 (+0.03)
Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal
at The Street - Mon Feb 23, 11:03AM CST
Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.
AGN: 240.22 (+2.88), VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), AZN: 69.29 (-0.81), SLXP: 172.96 (+0.15), ABBV: 65.99 (+0.02), HSP: 88.10 (-0.08)
Report: Valeant to buy Salix for $10.1B
Seeking Alpha - at Seeking Alpha - Sun Feb 22, 5:53AM CST
ENDP: 85.35 (+0.33), VRX: 224.63 (+1.81), SHPG: 254.45 (+3.99), SLXP: 172.96 (+0.15)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), MDT: 76.42 (+0.16), XON: 40.08 (-0.90), CTIC: 1.80 (+0.04), PFNX: 13.70 (+0.60), JNJ: 102.30 (+0.47), ANTM: 161.37 (+1.37), NVAX: 8.54 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), TBPH: 14.69 (-0.24), SNY: 50.52 (-0.27), ALQA: 4.48 (-0.27), REGN: 489.01 (-2.42), ONCY: 0.71 (unch), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), EPRS: 5.61 (-0.14), AMGN: 162.36 (+0.38), NKTR: 11.13 (+0.20), ZTS: 46.49 (+0.21), GILD: 109.30 (+0.56), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02)
Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST
TSLA: 248.84 (+4.74), VRX: 224.63 (+1.81), AMX: 21.00 (+0.22), HAL: 46.70 (+0.26), PBR: 10.13 (+0.20), ANTM: 161.37 (+1.37), FSLR: 56.72 (+0.16), SPY: 212.44 (+0.23), QQQ: 109.58 (unch), ARMH: 51.80 (-0.80), MSFT: 48.29 (-0.43), AAPL: 128.77 (-0.18), INTU: 102.33 (-1.49)
Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST
VRX: 224.63 (+1.81)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 224.63 (+1.81), VRX.TO: 270.02 (+2.67)
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon"
VRX: 224.63 (+1.81), VRX.TO: 270.02 (+2.67)
Is Valeant Making A Mistake By Purchasing Rights To Provenge?
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:22PM CST
VRX: 224.63 (+1.81)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.75 (+0.20), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), ZSPH: 49.05 (+0.07), RMTI: 10.03 (-0.25), BCLI: 3.66 (-0.04), SIEN: 19.84 (-0.77), JNJ: 102.30 (+0.47), ECYT: 6.02 (unch), SNY: 50.52 (-0.27), LENS: 8.79 (-0.21), REGN: 489.01 (-2.42), SYK: 95.51 (+0.25), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), APPY: 0.53 (+0.01), MNKD: 3.99 (+0.36), CELG: 115.53 (+0.45), ISRG: 503.66 (+1.31), GILD: 109.30 (+0.56), ANIP: 52.12 (+0.55), MRK: 60.23 (+0.45), ALXN: 160.56 (-1.13), CCXI: 7.21 (-0.09), ICPT: 306.23 (-0.84), AEZS: 0.43 (-0.01), ATRS: 2.08 (-0.09), NASH: 32.06 (+0.33)
Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
Dana Blankenhorn - at Seeking Alpha - Fri Jan 30, 11:12AM CST
BIIB: 391.24 (-3.11), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), XOM: 87.35 (+0.38), AMGN: 162.36 (+0.38), REGN: 489.01 (-2.42), SLB: 92.14 (-0.03), CELG: 115.53 (+0.45)
Wall Street Breakfast: Amazon Shares Surge After Profit Beat
Wall Street Breakfast - at Seeking Alpha - Fri Jan 30, 5:31AM CST
AMZN: 426.00 (-6.28), VRX: 224.63 (+1.81), SHAK: 69.39 (+3.89), OSTK: 22.37 (+0.66), CCRN: 10.71 (-0.03), LPG: 13.57 (+0.05), GOOG: 533.85 (-4.55), CVC: 20.43 (+0.13), PBR: 10.13 (+0.20), V: 69.57 (-0.43), SPY: 212.44 (+0.23), QQQ: 109.58 (unch), TRP: 45.39 (+0.69), XCO: 1.69 (unch), GOOGL: 546.49 (-2.71), HMC: 35.00 (-0.08), VZ: 49.79 (-0.18)
Dendreon's Asset Rummage Sale Completes the Circle of Life
at The Street - Fri Jan 30, 5:01AM CST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
VRX: 224.63 (+1.81), JUNO: 43.37 (-1.52)
Valeant to purchase Dendreon's Provenge
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 2:47AM CST
VRX: 224.63 (+1.81)